CSBIO(SZ:300255)2022-12-07 09:34Group 1: Company Overview - Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is involved in the production of heparin and related products [2] - The company has received registration approval for its new product, Dahuansuan, and has passed the new GMP certification [2] Group 2: Product Development and Market Strategy - The company is actively developing new products, including low molecular weight heparin and Eptifibatide, which are currently awaiting approval [2] - The market for hyaluronic acid appears promising, although current production levels are low [3] Group 3: Supply Chain and Production - The company primarily sources heparin raw materials domestically, with foreign procurement being a minor part [3] - The production workshop for formulations is built according to FDA standards [3] Group 4: Market Coverage and Sales - The low molecular weight heparin injection has approximately 50% coverage in top-tier hospitals, with nearly 2,000 hospitals nationwide using the product [3] - The company’s Dahuansuan raw material is mainly for internal use, while the Jiangsu subsidiary sells its heparin sodium raw materials externally [3]